Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Co. is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). In addition, Co. is developing a diagnostic device via a mobile device. Co. also has interests in certain other assets being developed by third parties including HT-005 for patients with lupus and potential product candidates being developed for the prevention of COVID-19. The HOTH average annual return since 2019 is shown above.
The Average Annual Return on the HOTH average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HOTH average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HOTH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|